KDM3A and cancer: In Hepatocellular Carcinoma (HCC) and other cancers (e.g., Ewing Sarcoma), the miR-22-mediated post-transcriptional silencing of histone deacetylases HDAC4 [35] or KDM3A (lysine (k)-specific demethylase 3A) [36], with consequent inhibition of tumorigenesis, has been evidenced, once again, by in vitro and in vivo xenograft models, using immunocompromised mice.